Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetes

J Diabetes Complications. 2018 Sep;32(9):830-832. doi: 10.1016/j.jdiacomp.2018.07.003. Epub 2018 Jul 11.

Abstract

A rapid decline in estimated glomerular filtration rate over 2 years in a large hypertensive cohort was associated with similar risks for overall cardiovascular disease in people with or without diabetes mellitus, but with higher all-cause mortality, heart failure, and end stage renal disease risk in people with diabetes.

Trial registration: ClinicalTrials.gov NCT00000542.

Keywords: CVD risk; Heart failure; Mortality risk; Renal failure; Type 2 diabetes; eGFR change.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / analysis
  • Cardiovascular Diseases / diagnosis*
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / physiopathology
  • Cause of Death
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / diagnosis*
  • Diabetes Mellitus, Type 2 / mortality*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diabetic Angiopathies / diagnosis
  • Diabetic Angiopathies / mortality
  • Diabetic Angiopathies / physiopathology
  • Diabetic Nephropathies / diagnosis
  • Diabetic Nephropathies / mortality
  • Diabetic Nephropathies / physiopathology
  • Disease Progression
  • Female
  • Glomerular Filtration Rate / physiology*
  • Humans
  • Hypertension / complications
  • Hypertension / diagnosis*
  • Hypertension / mortality*
  • Kidney Failure, Chronic / diagnosis*
  • Kidney Failure, Chronic / mortality
  • Kidney Failure, Chronic / physiopathology
  • Male
  • Middle Aged
  • Mortality
  • Prognosis
  • Risk Factors

Substances

  • Biomarkers

Associated data

  • ClinicalTrials.gov/NCT00000542